$TTOO
T2 Biosystems, Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037656 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $5.483M $3.677M $7.428M
YoY Change -21.45% -50.5% 41.62%
Cost Of Revenue $3.768M $6.085M $4.720M
YoY Change -29.73% 28.92% -30.89%
Gross Profit $1.715M -$2.408M $2.708M
YoY Change 6.0% -188.92% -270.31%
Gross Profit Margin 31.28% -65.49% 36.46%
Selling, General & Admin $6.673M $7.017M $8.536M
YoY Change 1.97% -17.8% 67.93%
% of Gross Profit 389.1% 315.21%
Research & Development $4.876M $6.375M $6.384M
YoY Change -8.91% -0.14% 61.01%
% of Gross Profit 284.31% 235.75%
Depreciation & Amortization $255.0K $300.0K $300.0K
YoY Change -5.56% 0.0% -25.0%
% of Gross Profit 14.87% 11.08%
Operating Expenses $11.55M $13.39M $14.92M
YoY Change -2.93% -10.24% 64.9%
Operating Profit -$9.834M -$15.80M -$12.21M
YoY Change -4.33% 29.38% 14.82%
Interest Expense -$675.0K $1.560M -$1.913M
YoY Change -63.71% -181.55% 196.13%
% of Operating Profit
Other Income/Expense, Net $96.00K -$1.575M $163.0K
YoY Change -2020.0% -1066.26% 503.7%
Pretax Income -$10.41M -$17.38M -$13.96M
YoY Change -14.25% 24.44% 24.0%
Income Tax
% Of Pretax Income
Net Earnings -$10.41M -$17.38M -$13.96M
YoY Change -14.25% 24.44% 24.05%
Net Earnings / Revenue -189.91% -472.53% -187.96%
Basic Earnings Per Share -$2.95 -$4.21
Diluted Earnings Per Share -$1.41 -$2.95 -$84.17K
COMMON SHARES
Basic Shares Outstanding 7.319M 352.5M 3.318M
Diluted Shares Outstanding 6.009M 3.318M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.33M $20.37M $42.09M
YoY Change -67.96% -51.61% -31.29%
Cash & Equivalents $10.33M $20.37M $22.05M
Short-Term Investments $0.00 $0.00 $20.04M
Other Short-Term Assets $2.582M $2.690M $3.327M
YoY Change -16.98% -19.15% 12.02%
Inventory $4.349M $4.242M $4.822M
Prepaid Expenses
Receivables $2.163M $1.578M $4.222M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.42M $28.88M $54.46M
YoY Change -56.25% -46.98% 5.85%
LONG-TERM ASSETS
Property, Plant & Equipment $13.27M $4.734M $3.813M
YoY Change 183.94% 24.15% 6.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $1.694M $153.0K $1.712M
YoY Change 1007.19% -91.06% 151.76%
Total Long-Term Assets $14.97M $15.08M $15.58M
YoY Change -7.29% -3.22% -40.5%
TOTAL ASSETS
Total Short-Term Assets $19.42M $28.88M $54.46M
Total Long-Term Assets $14.97M $15.08M $15.58M
Total Assets $34.39M $43.95M $70.04M
YoY Change -43.19% -37.24% -9.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.296M $2.063M $2.616M
YoY Change -54.24% -21.14% 8.55%
Accrued Expenses $8.999M $8.531M $8.169M
YoY Change 7.93% 4.43% 6.73%
Deferred Revenue $172.0K $163.0K
YoY Change -66.8%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.51M $10.94M $11.40M
YoY Change -10.11% -3.99% 10.11%
LONG-TERM LIABILITIES
Long-Term Debt $49.65M $49.19M $47.13M
YoY Change 3.89% 4.36% 5.65%
Other Long-Term Liabilities $14.20M $4.791M $13.97M
YoY Change 210.31% -65.71% 353.57%
Total Long-Term Liabilities $63.85M $4.791M $61.10M
YoY Change 1295.11% -92.16% 1883.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.51M $10.94M $11.40M
Total Long-Term Liabilities $63.85M $4.791M $61.10M
Total Liabilities $74.36M $15.73M $72.50M
YoY Change 357.18% -78.3% 439.8%
SHAREHOLDERS EQUITY
Retained Earnings -$534.2M -$524.1M -$460.1M
YoY Change 13.13% 13.91% 11.38%
Common Stock $494.6M $492.5M
YoY Change 7.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$39.97M -$31.70M -$2.500M
YoY Change
Total Liabilities & Shareholders Equity $34.39M $43.95M $70.04M
YoY Change -43.19% -37.24% -9.78%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$10.41M -$17.38M -$13.96M
YoY Change -14.25% 24.44% 24.05%
Depreciation, Depletion And Amortization $255.0K $300.0K $300.0K
YoY Change -5.56% 0.0% -25.0%
Cash From Operating Activities -$10.33M -$15.90M -$9.727M
YoY Change 4.95% 63.49% 55.88%
INVESTING ACTIVITIES
Capital Expenditures $36.00K -$126.0K $42.00K
YoY Change -118.09% -400.0% -114.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$36.00K -$126.0K $42.00K
YoY Change -100.37% -400.0% -100.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 748.0K 23.18M 24.00K
YoY Change 212.97% 96495.83% -99.93%
NET CHANGE
Cash From Operating Activities -10.33M -15.90M -9.727M
Cash From Investing Activities -36.00K -126.0K 42.00K
Cash From Financing Activities 748.0K 23.18M 24.00K
Net Change In Cash -9.617M 7.154M -9.661M
YoY Change -4957.07% -174.05% 36.07%
FREE CASH FLOW
Cash From Operating Activities -$10.33M -$15.90M -$9.727M
Capital Expenditures $36.00K -$126.0K $42.00K
Free Cash Flow -$10.37M -$15.78M -$9.769M
YoY Change 7.49% 61.5% 64.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-36571
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4827488
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Central Index Key
EntityCentralIndexKey
0001492674
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7319105
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20366000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22245000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9996000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5134000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3909000
dei Entity Address Address Line1
EntityAddressAddressLine1
101 Hartwell Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4646
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1551000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2832000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8338000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
163000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
518000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10943000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11688000
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
49188000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
47790000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8569000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9359000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4791000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-31669000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43952000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-524120000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4577000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
492444000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
459314000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-12903000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60539000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4242000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2690000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4734000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9058000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 us-gaap Assets Current
AssetsCurrent
28876000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1131000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2022Q3 us-gaap Assets
Assets
43952000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1792000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2466000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
24000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7050849
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7050849
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3328017
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3328017
us-gaap Net Income Loss
NetIncomeLoss
-51904000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Registrant Name
EntityRegistrantName
T2 Biosystems, Inc.
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
TTOO
CY2021Q4 us-gaap Assets Current
AssetsCurrent
44394000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4675000
CY2021Q4 us-gaap Assets
Assets
60539000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2063000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8531000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2552000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1578000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3110000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9766000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
186000
CY2022Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
3000
CY2022Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3000
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3000
CY2022Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
330000000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
330000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9997000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-45676000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-472216000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3677000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7428000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16822000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21078000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6375000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6384000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21056000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16448000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7017000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8536000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24071000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21983000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
19477000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
19640000
us-gaap Costs And Expenses
CostsAndExpenses
62498000
us-gaap Costs And Expenses
CostsAndExpenses
53772000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15800000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12212000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32694000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
18000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1560000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1919000
us-gaap Interest Expense
InterestExpense
4556000
us-gaap Interest Expense
InterestExpense
5642000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-117000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1792000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1010000
CY2022Q3 ttoo Change In Fair Value Of Derivative Warrant Liability
ChangeInFairValueOfDerivativeWarrantLiability
179000
ttoo Change In Fair Value Of Derivative Warrant Liability
ChangeInFairValueOfDerivativeWarrantLiability
179000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-78000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
163000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
211000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1575000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1750000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6228000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4403000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17375000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13962000
us-gaap Net Income Loss
NetIncomeLoss
-51904000
us-gaap Net Income Loss
NetIncomeLoss
-37097000
CY2022Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
330000
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
330000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17705000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13962000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52234000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37097000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-31669000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.95
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.95
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.21
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.86
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6008819
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6008819
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3317646
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3317646
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4323452
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4323452
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3127951
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3127951
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17375000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13962000
us-gaap Net Income Loss
NetIncomeLoss
-37097000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
2000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
9000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-2000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
14000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17375000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13962000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-51900000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-37102000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8726000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1308000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
53000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10660000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-566000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1843000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
251000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19968000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12475000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
9009000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13962000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-2463000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-12903000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
231000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1433000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16495000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25651000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1534000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
139000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
12000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4494000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18034000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-37519000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1372000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22183000
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
330000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17375000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
692000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22047000
us-gaap Profit Loss
ProfitLoss
-51904000
us-gaap Profit Loss
ProfitLoss
-37097000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
792000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
114000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
907000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
982000
us-gaap Share Based Compensation
ShareBasedCompensation
5458000
us-gaap Share Based Compensation
ShareBasedCompensation
5617000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1792000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1010000
ttoo Change In Fair Value Of Derivative Warrant Liability
ChangeInFairValueOfDerivativeWarrantLiability
179000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
-2000
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
14000
ttoo Gain Loss On Issuance Of Series A Redeemable Convertible Preferred Stock And Derivative Warrant Liability
GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability
-65000
us-gaap Production Related Impairments Or Charges
ProductionRelatedImpairmentsOrCharges
30000
us-gaap Paid In Kind Interest
PaidInKindInterest
1613000
us-gaap Paid In Kind Interest
PaidInKindInterest
2803000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3556000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-877000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-356000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
815000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1915000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-791000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
523000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
61000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
619000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-375000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
9000
ttoo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-868000
ttoo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-848000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29032000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
15251000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
9998000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
303000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9695000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14990000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
243000
ttoo Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises
ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises
139000
ttoo Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises
ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises
328000
ttoo Proceeds From Issuance Initial Public Offering Net Of Offering Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
28110000
ttoo Proceeds From Issuance Initial Public Offering Net Of Offering Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
19968000
ttoo Proceeds From Issuance Of Series A Convertible Redeemable Preferred Stock And Derivative Warrant Liability
ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability
300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28306000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20296000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2299000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6254000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23796000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17344000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21497000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23598000
us-gaap Interest Paid Net
InterestPaidNet
2916000
us-gaap Interest Paid Net
InterestPaidNet
2815000
ttoo Transfer Of T2 Owned Instruments And Components To From Inventory
TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
-482000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1131000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1551000
ttoo Transfer Of T2 Owned Instruments And Components To From Inventory
TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
-729000
ttoo Deemed Dividend On Series A Convertible Redeemable Preferred Stock
DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock
330000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
199000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
72000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
80000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20366000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21497000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23598000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an <span style="font-style:italic;">in vitro</span> diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). The Company’s initial development efforts target the detection of pathogens that cause sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2022, the Company had cash, cash equivalents, and restricted cash of $21.5 million, an accumulated deficit of $524.1 million and stockholders’ deficit of $31.7 million. The Company has historically experienced cash outflows from operating activities. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through proceeds from its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (“PIPE”) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 8), its March 2021 establishment of an Equity Distribution Agreement (Note 8), private placements of redeemable convertible preferred stock as well as borrowings from debt financing arrangements. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact the Company’s operations. Although the Company did not see any material impact to accounts receivable during the three and nine month period ended September 30, 2022, the Company’s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue its future product development may be impacted. The ability of the Company’s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since authorization from the United States Food and Drug Administration, or FDA, was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and Emergency Use Authorization, or EUA, was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. If the FDA rescinds EUA, the Company would be unable to sell its T2SARS-CoV-2 tests. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (“ASC”) 205-40, <span style="font-style:italic;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span>, management must evaluate whether there are conditions or events, considered in the </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of our operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (“CRG”) (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $5.0 million. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s stock had been trading under $1.00 since September 27, 2021. <span style="color:#000000;">On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company’s common stock being below </span>$1.00 <span style="color:#000000;">per share for thirty consecutive business days (the “Bid Price Rule”). Under the Nasdaq rules, the Company had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of $</span>1.00 per share of the Company’s common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, the Company received a letter from Nasdaq informing the Company that its shares of common stock have failed to comply with the Bid Price Rule for continued listing and, as a result, the Company’s shares were subject to delisting. The letter further stated that the Company may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the “Panel”).</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company filed an appeal and hearing request to the Nasdaq Staff’s determination to stay the delisting of the Company’s shares of common stock from Nasdaq pending the Panel’s decision. The Nasdaq Staff informed the Company that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2022, the Company received a letter from the Nasdaq notifying the Company that the Nasdaq had granted the Company’s request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and the Company’s request for an exception to the Bid Price Rule until November 1, 2022. </p><p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directors approved the reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000445">50 pre-split shares</span>, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 22, 2022, the Company received a letter from the Nasdaq (the “Nasdaq Staff Deficiency Letter”) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).  In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until January 18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(b)(2) if at any time before January 18, 2023, the Company maintains its MVLS at $35 million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company’s common stock.  If compliance is not achieved by January 18, 2023, the Company expects that Nasdaq would provide written notification to the Company that its securities are subject to delisting. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">Notice, the Nasdaq notified the Company that, from August 10, 2022 to August 23, 2022, the Company’s MVLS had been $</span><span style="color:#000000;">35</span><span style="color:#000000;"> million or greater and, accordingly, the Company had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company’s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.<span style="color:#000000;"> The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p>
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21500000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-524100000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-31700000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21500000
CY2021Q4 ttoo Minimum Bid Price Of Common Stock
MinimumBidPriceOfCommonStock
1.00
CY2022Q3 ttoo Minimum Market Value Of Listed Securities
MinimumMarketValueOfListedSecurities
35000000
CY2022Q3 ttoo Minimum Market Value Of Listed Securities
MinimumMarketValueOfListedSecurities
35000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10000000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9996000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
10000000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
9996000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10000000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9996000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2022 and December 31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p>
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3677000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7428000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16822000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21078000
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
100000
us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.86
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
200000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
400000
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1675000
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1792000
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2195000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1591000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1231000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
953000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
816000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1365000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4242000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3909000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20934000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20107000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16200000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15432000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4734000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4675000
CY2022Q3 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1000000.0
CY2021Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1400000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000.0
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3894000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3687000
CY2022Q3 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1482000
CY2021Q4 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1250000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
392000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
384000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
1000000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
974000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1295000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1174000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
468000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
869000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8531000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8338000
CY2022Q3 ttoo Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs
DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts
51597000
CY2021Q4 ttoo Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs
DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts
49364000
CY2022Q3 ttoo Debt Instrument Unaccrued Paid In Kind Interest
DebtInstrumentUnaccruedPaidInKindInterest
2233000
CY2021Q4 ttoo Debt Instrument Unaccrued Paid In Kind Interest
DebtInstrumentUnaccruedPaidInKindInterest
1287000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
176000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
287000
CY2022Q3 us-gaap Notes Payable
NotesPayable
49188000
CY2021Q4 us-gaap Notes Payable
NotesPayable
47790000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1354000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2423000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5440000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5573000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
485323
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
485323
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
342895
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
342895
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.
ttoo Stock Issued And Outstanding During Period Shares Stock Splits
StockIssuedAndOutstandingDuringPeriodSharesStockSplits
352957478
ttoo Stock Outstanding During Period Shares Stock Splits
StockOutstandingDuringPeriodSharesStockSplits
7,059,144
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
345898334

Files In Submission

Name View Source Status
0001564590-22-037656-index-headers.html Edgar Link pending
0001564590-22-037656-index.html Edgar Link pending
0001564590-22-037656.txt Edgar Link pending
0001564590-22-037656-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g1b2xf54kzm3000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ttoo-10q_20220930.htm Edgar Link pending
ttoo-20220930.xsd Edgar Link pending
ttoo-20220930_cal.xml Edgar Link unprocessable
ttoo-10q_20220930_htm.xml Edgar Link completed
ttoo-ex104_892.htm Edgar Link pending
ttoo-ex105_1066.htm Edgar Link pending
ttoo-ex311_11.htm Edgar Link pending
ttoo-ex312_12.htm Edgar Link pending
ttoo-ex321_14.htm Edgar Link pending
ttoo-ex322_7.htm Edgar Link pending
ttoo-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ttoo-20220930_lab.xml Edgar Link unprocessable
ttoo-20220930_def.xml Edgar Link unprocessable